Systemic sclerosis & Raynaud's
Long-term effects of selexipag in SSc-associated digital ulcers: a case-control multicentre observational study
Authors' conclusion
This observational study suggests that selexipag may be strongly effective in treating DUs refractory to conventional drugs.
Study context
- Population
- SSc patients with refractory digital ulcersmatched case-control
- Participants
- 96 patients
- Comparison
- Selexipag vs iloprost for refractory SSc-associated digital ulcers (DUs)
- Selexipagn = 32
- Iloprostn = 64reference
- Outcome
- DU healing rate (long-term efficacy in treating DUs)
- Follow-up
- 96 weeks
Methodological detailsmulticentre, matched for gender, disease subset and age, Kaplan-Meier analysis
- Multicentre
- Matched for gender, disease subset and age
- Kaplan-Meier analysis
Main finding
As reported in the abstract
DU healing rate
P < 0.001
Observational data: associations, not effects.
Further findings
DU relapse rate · 24 months
P < 0.001
New DU formation · 24 months
P < 0.001
| Outcome | Selexipag | Iloprost |
|---|---|---|
| Time to healing · week 40 | 75% | — not stated in the abstract |
— not stated in the abstract
- DU number, Raynaud Condition Score (RCS) and Likert Pain Scale (LPS) · throughout 24 months
- P < 0.001 for all
DU number, RCS and LPS · throughout 24 months
- Significant improvement with selexipag vs iloprost
Time to healing · week 40
- Faster healing with selexipag
Original publication
Long-term effects of selexipag in SSc-associated digital ulcers: a case-control multicentre observational study. Rheumatology (Oxford). Published 3 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →